In this study, we measured the pretreatment serum sPD‐L1 level in patients with advanced NSCLC who received anti‐PD‐1 antibody and assessed the relationship between the serum sPD‐L1 level and the clinical characteristics, PD‐L1 expression on tumor cells, the response to anti‐PD‐1 antibody, and patient outcome. Here, CD274 is linked to non-small cell lung carcinoma.